Psilocybin could be the key to unlocking key treatments for mental health issues. “Existing antidepressant drugs don’t work well for an estimated 30 to 50 percent of the people who try them; when they do work, the effects can take weeks to kick in. Psilocybin, a compound that can profoundly alter consciousness and perceptions of reality, might be a powerful alternative, says Roland Griffiths, a neuropsychopharmacologist at Johns Hopkins School of Medicine,” as quoted by Science News.

Better still, the drug can reportedly promote neuroplasticity in the brains of rats. According to a study in the Journal of Psychopharmacology, “The present study demonstrates that psilocybin rapidly induces gene expression related to neuroplasticity, biased towards the prefrontal cortex, compared to the hippocampus. Findings provide further evidence for the rapid plasticity-promoting effects of psilocybin.”


The U.S. is seeing broader support of psilocybin use, as well.

For example, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, “An estimated 1 in every 5 adults in Oregon is coping with a mental health condition,” 20 doctors and other health care workers wrote in the voters’ pamphlet.

“We support Measure 109 because it provides a new treatment for many that might break through where others fall short.”

Better Plant Sciences (CSE: PLNT) (OTCQB: VEGGF) Just Received Health Canada Approval to Advance its Psilocybin Research

The company just announced that its majority owned subsidiary NeonMind Biosciences obtained Health Canada approval to advance its preclinical trial on psilocybin-based research. The Trial is intended to determine the capacity of psilocybin to dose-dependently cause weight loss and prevent weight gain, measuring glucose metabolism, weight loss and effect on food cravings.

NeonMind has engaged the University of British Columbia to conduct the Trial. The services are provided by the University under the supervision of Dr. Alasdair Barr, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, who is authorized by Health Canada to act as the Principal Investigator for the Trial.

Dr. Barr is a tenured faculty member at the University and has extensive experience working with controlled substances as part of his research. His doctoral and post-doctoral research involved a significant body of work using controlled substances.

Before psilocybin, a restricted substance, can be used for a scientific purpose in Canada, the Canadian Minister of Health must grant authority or an exemption pursuant to Subsection 56 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

On July 27, 2020, an application regarding the NeonMind Trial was submitted to Health Canada and on October 7, 2020, pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR), Health Canada granted authorization to the Principal Investigator to carry out the Trial using psilocybin at UBC.

For more information, visit the company’s website at https://betterplantsciences.com.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.

Contact Information:
2818047972
ty@lifewatermedia.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68472

News Provided by Newsfile via QuoteMedia

  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less